362 related articles for article (PubMed ID: 23426530)
1. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
[TBL] [Abstract][Full Text] [Related]
2. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
Lugo G; Castañeda-Hernández G
Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
[TBL] [Abstract][Full Text] [Related]
7. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
[TBL] [Abstract][Full Text] [Related]
8. Aminoglycoside volume of distribution and illness severity in critically ill septic patients.
Marik PE
Anaesth Intensive Care; 1993 Apr; 21(2):172-3. PubMed ID: 8517507
[TBL] [Abstract][Full Text] [Related]
9. Estimation of once-daily amikacin dose in critically ill adults.
Šíma M; Hartinger J; Cikánková T; Slanař O
J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
[TBL] [Abstract][Full Text] [Related]
10. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.
Gálvez R; Luengo C; Cornejo R; Kosche J; Romero C; Tobar E; Illanes V; Llanos O; Castro J
Int J Antimicrob Agents; 2011 Aug; 38(2):146-51. PubMed ID: 21612894
[TBL] [Abstract][Full Text] [Related]
11. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
[TBL] [Abstract][Full Text] [Related]
13. Amikacin population pharmacokinetics among paediatric burn patients.
Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
[TBL] [Abstract][Full Text] [Related]
15. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
Roger C; Nucci B; Louart B; Friggeri A; Knani H; Evrard A; Lavigne JP; Allaouchiche B; Lefrant JY; Roberts JA; Muller L
J Antimicrob Chemother; 2016 Jan; 71(1):208-12. PubMed ID: 26429564
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of amikacin in preterm and term infants.
Siddiqi A; Khan DA; Khan FA; Razzaq A
Singapore Med J; 2009 May; 50(5):486-9. PubMed ID: 19495517
[TBL] [Abstract][Full Text] [Related]
17. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
18. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
[TBL] [Abstract][Full Text] [Related]
19. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
Marsot A; Guilhaumou R; Riff C; Blin O
Clin Pharmacokinet; 2017 Feb; 56(2):127-138. PubMed ID: 27324191
[TBL] [Abstract][Full Text] [Related]
20. Individualizing amikacin regimens: accurate method to achieve therapeutic concentrations.
Zaske DE; Cipolle RJ; Rotschafer JC; Kohls PR; Strate RG
Ther Drug Monit; 1991 Nov; 13(6):502-6. PubMed ID: 1771647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
